Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)

NCT07678775 is registered in ClinicalTrials.gov with ML Bio Solutions, Inc. as lead sponsor.

NCT NCT07678775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07678775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants With Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
Lead sponsor
ML Bio Solutions, Inc.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
June 5, 2026
Completion date
October 31, 2030
Enrollment
107 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

limb-girdle muscular dystrophy type 2i (lgmd2i)